'Pipeline' Device Offers New Option for Difficult-to-Treat Brain Aneurysms

Source: Science Daily (12/3/12)

"The study reflects the increased emphasis on collecting post-marketing data on newly approved medical devices to see if the results in initial clinical experience are comparable to those in research trials."

A new technology called the Pipeline embolization device (PED) shows encouraging results in patients with certain types of difficult-to-treat brain aneurysms, reports the December issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

Data collected since the PED was approved for marketing show generally good results in "real world" clinical practice. However, the report raises concerns about fatal bleeding and other serious complications, especially for aneurysms in one specific location. The lead author of the study was Dr. Peter Kan of University at Buffalo, N.Y.

The researchers evaluated "early postmarket" results -- that is, after approval by the U.S. Food and Drug Administration (FDA) -- using the PED at seven surgical centers. . .View Full Article

Interim Data From TID Trial Are Positive
Source: Streetwise Reports (05/15/2025)

Sernova Biotherapeutics Inc.'s (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) regenerative treatment delivered via its Cell Pouch Bio-hybrid Organ is proving to result in insulin independence, among other outcomes. Read what one analyst says are the implications of this clear medical benefit.

One Co. With Cell Holding Device Stands Out in T1D Space
Source: Dr. Joseph Pantginis (04/28/2025)

Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) alone has shown favorable outcomes in a trial when patients with this disease were treated with an implanted device containing donor islets, noted an H.C. Wainwright & Co. report.

Cell Pouch Co. Peer Aborts Program Using Like Device
Source: Dr. Douglas Loe (04/03/2025)

The implications for Cell Pouch, an implantable cell delivery vehicle, and the biotech behind it are positive, noted a Leede Financial Inc. report.

Regenerative Medicine Firm OK'd To Advance Trial in T1D
Source: Streetwise Reports (04/03/2025)

Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) says the Data Safety Monitoring Board supports the ongoing evaluation of the biotech's Cell Pouch Bio-hybrid Organ in this indication.

Clean Tech Co. Achieves Record-Breaking Revenue for Exceptional Growth
Source: Streetwise Reports (04/01/2025)

BioLargo Inc. (BLGO:OTCQX) announced in its annual report that in 2024 it saw record revenues and an increase of 45% over the year before. Read why an expert and an analyst both like this clean technology company's story.